Janus Kinase (JAK)/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis
Authors' conclusion
Our preliminary results demonstrate that tofacitinib modulates the innate immune response by reducing the frequency of ILC1 cells and their production of IFN-γ.
Study context
- Population
- Rheumatoid arthritis (RA) patients starting tofacitinib or anti-TNFα
- Participants
- 20 vs 10
- Comparison
- Tofacitinib vs anti-TNFα in RA patients; ILC1 and ILC3 before and 3 months after therapy
- Tofacitinibn = 20
- Anti-TNFαn = 10reference
- Outcome
- ILC1 and ILC3 frequencies and their production of IFN-γ and IL-17 (flow cytometry)
- Follow-up
- Three months after therapy
Methodological detailsex vivo and in vitro, flow cytometry
- Ex vivo and in vitro
- Flow cytometry
Main finding
As reported in the abstract
three months
- RA patients showed a significant expansion of ILC1 but not ILC3
- Tofacitinib: overall ILC frequency reduced after 3 months, as was ILC1 ability to release IFN-γ
- Anti-TNFα: no reduction in innate lymphoid cells (ILCs)
- In vitro tofacitinib: dose-dependent reduction in ILC frequency vs untreated cells
Original publication
JAK/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis. Clin Exp Rheumatol. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →